22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • Chikungunya fever is caused by a mosquito-borne alphavirus originating in East Africa.

          • During the past 7 years, the disease has spread to islands of the Indian Ocean, Asia and Europe.

          • Its spread has been facilitated by a mutation favouring replication in the mosquito Ae. albopictus.

          • No vaccines or antiviral drugs are available to prevent or treat chikungunya fever.

          • This paper provides an extensive review of the virus and disease, including Supplementary Tables.

          Abstract

          Chikungunya virus (CHIKV) is the aetiological agent of the mosquito-borne disease chikungunya fever, a debilitating arthritic disease that, during the past 7 years, has caused immeasurable morbidity and some mortality in humans, including newborn babies, following its emergence and dispersal out of Africa to the Indian Ocean islands and Asia. Since the first reports of its existence in Africa in the 1950s, more than 1500 scientific publications on the different aspects of the disease and its causative agent have been produced. Analysis of these publications shows that, following a number of studies in the 1960s and 1970s, and in the absence of autochthonous cases in developed countries, the interest of the scientific community remained low. However, in 2005 chikungunya fever unexpectedly re-emerged in the form of devastating epidemics in and around the Indian Ocean. These outbreaks were associated with mutations in the viral genome that facilitated the replication of the virus in Aedes albopictus mosquitoes. Since then, nearly 1000 publications on chikungunya fever have been referenced in the PubMed database. This article provides a comprehensive review of chikungunya fever and CHIKV, including clinical data, epidemiological reports, therapeutic aspects and data relating to animal models for in vivo laboratory studies. It includes Supplementary Tables of all WHO outbreak bulletins, ProMED Mail alerts, viral sequences available on GenBank, and PubMed reports of clinical cases and seroprevalence studies.

          Related collections

          Most cited references230

          • Record: found
          • Abstract: found
          • Article: not found

          Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.

          The interferon (IFN) system is an extremely powerful antiviral response that is capable of controlling most, if not all, virus infections in the absence of adaptive immunity. However, viruses can still replicate and cause disease in vivo, because they have some strategy for at least partially circumventing the IFN response. We reviewed this topic in 2000 [Goodbourn, S., Didcock, L. & Randall, R. E. (2000). J Gen Virol 81, 2341-2364] but, since then, a great deal has been discovered about the molecular mechanisms of the IFN response and how different viruses circumvent it. This information is of fundamental interest, but may also have practical application in the design and manufacture of attenuated virus vaccines and the development of novel antiviral drugs. In the first part of this review, we describe how viruses activate the IFN system, how IFNs induce transcription of their target genes and the mechanism of action of IFN-induced proteins with antiviral action. In the second part, we describe how viruses circumvent the IFN response. Here, we reflect upon possible consequences for both the virus and host of the different strategies that viruses have evolved and discuss whether certain viruses have exploited the IFN response to modulate their life cycle (e.g. to establish and maintain persistent/latent infections), whether perturbation of the IFN response by persistent infections can lead to chronic disease, and the importance of the IFN system as a species barrier to virus infections. Lastly, we briefly describe applied aspects that arise from an increase in our knowledge in this area, including vaccine design and manufacture, the development of novel antiviral drugs and the use of IFN-sensitive oncolytic viruses in the treatment of cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Spread of the tiger: global risk of invasion by the mosquito Aedes albopictus.

            Aedes albopictus, commonly known as the Asian tiger mosquito, is currently the most invasive mosquito in the world. It is of medical importance due to its aggressive daytime human-biting behavior and ability to vector many viruses, including dengue, LaCrosse, and West Nile. Invasions into new areas of its potential range are often initiated through the transportation of eggs via the international trade in used tires. We use a genetic algorithm, Genetic Algorithm for Rule Set Production (GARP), to determine the ecological niche of Ae. albopictus and predict a global ecological risk map for the continued spread of the species. We combine this analysis with risk due to importation of tires from infested countries and their proximity to countries that have already been invaded to develop a list of countries most at risk for future introductions and establishments. Methods used here have potential for predicting risks of future invasions of vectors or pathogens.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus.

                Bookmark

                Author and article information

                Contributors
                Journal
                Antiviral Res
                Antiviral Res
                Antiviral Research
                Elsevier B.V.
                0166-3542
                1872-9096
                28 June 2013
                September 2013
                28 June 2013
                : 99
                : 3
                : 345-370
                Affiliations
                [a ]UMR_D 190 “Emergence des Pathologies Virales” (Aix-Marseille Univ. IRD French Institute of Research for Development EHESP French School of Public Health), Marseille, France
                [b ]University Hospital Institute for Infectious Disease and Tropical Medicine, Marseille, France
                [c ]CEA, Division of Immuno-Virologie, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses, France
                [d ]UMR E1, University Paris Sud 11, Orsay, France
                Author notes
                [* ]Corresponding author. Current address: UMR_D 190, Faculté de Médecine Timone, 5ème étage Aile Bleue, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France. Tel.: +33 91 32 44 20; fax: +33 91 32 44 21. djamt@ 123456yahoo.fr
                Article
                S0166-3542(13)00166-6
                10.1016/j.antiviral.2013.06.009
                7114207
                23811281
                00eb26a1-b909-472d-975e-a157d0597d62
                Copyright © 2013 Elsevier B.V. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 7 April 2013
                : 21 May 2013
                : 18 June 2013
                Categories
                Article

                Infectious disease & Microbiology
                chikungunya virus,chikungunya fever,arbovirus,alphavirus,antiviral therapy

                Comments

                Comment on this article